Branden J Stansley1, Bryan K Yamamoto. 1. Department of Neurosciences, University of Toledo College of Medicine, 3000 Arlington Avenue, Mail Stop 1007, Toledo, OH, 43614, USA.
Abstract
RATIONALE: L-dopa, the main therapeutic for Parkinson's disease (PD), has been shown to increase brain dopamine concentrations that are necessary for proper motor control; however, PD patients experience non-motor symptoms that are not improved or could be exacerbated by L-dopa. OBJECTIVES: The purpose of this study is to determine the effects of L-dopa treatment on cognitive and affective behavioral responses of rats, as well as their corresponding monoamine brain concentrations. METHODS: Rats were treated with L-dopa (6 mg/kg; twice daily) for 10 consecutive days. Sodium ascorbate (400 mg/kg) was co-administered with L-dopa to investigate the effects of antioxidant co-treatment on behavior and monoamine concentrations. Rats underwent cognitive and affective behavioral testing. Monoamine concentrations of several brain regions were analyzed. RESULTS: L-dopa treatment resulted in significant impairment in the performance in the Barnes maze and improvement in conditioned fear stress paradigms. Specifically, L-dopa caused an increase in latency to find the goal box during Barnes maze testing and increased freezing behavior in context-induced conditioned fear testing. Furthermore, the rats in the conditioned fear stress experiments showed corresponding depletions in serotonin (5-HT) and its metabolite, 5-HIAA, in the dorsal raphe nucleus (DRN) and the mPFC. The behavioral impairments as well as monoamine depletions were blocked by ascorbate co-treatment. CONCLUSIONS: Chronic L-dopa may contribute to non-motor symptoms related to spatial memory and fear. These effects may be attributable to a dysregulation of brain 5-HT caused by L-dopa treatment. The results presented here provide further rationale for investigating adjunctive therapeutics to L-dopa for PD, such as antioxidants.
RATIONALE: L-dopa, the main therapeutic for Parkinson's disease (PD), has been shown to increase brain dopamine concentrations that are necessary for proper motor control; however, PDpatients experience non-motor symptoms that are not improved or could be exacerbated by L-dopa. OBJECTIVES: The purpose of this study is to determine the effects of L-dopa treatment on cognitive and affective behavioral responses of rats, as well as their corresponding monoamine brain concentrations. METHODS:Rats were treated with L-dopa (6 mg/kg; twice daily) for 10 consecutive days. Sodium ascorbate (400 mg/kg) was co-administered with L-dopa to investigate the effects of antioxidant co-treatment on behavior and monoamine concentrations. Rats underwent cognitive and affective behavioral testing. Monoamine concentrations of several brain regions were analyzed. RESULTS:L-dopa treatment resulted in significant impairment in the performance in the Barnes maze and improvement in conditioned fear stress paradigms. Specifically, L-dopa caused an increase in latency to find the goal box during Barnes maze testing and increased freezing behavior in context-induced conditioned fear testing. Furthermore, the rats in the conditioned fear stress experiments showed corresponding depletions in serotonin (5-HT) and its metabolite, 5-HIAA, in the dorsal raphe nucleus (DRN) and the mPFC. The behavioral impairments as well as monoamine depletions were blocked by ascorbate co-treatment. CONCLUSIONS: Chronic L-dopa may contribute to non-motor symptoms related to spatial memory and fear. These effects may be attributable to a dysregulation of brain 5-HT caused by L-dopa treatment. The results presented here provide further rationale for investigating adjunctive therapeutics to L-dopa for PD, such as antioxidants.
Authors: Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop Journal: Behav Pharmacol Date: 2010-10 Impact factor: 2.293
Authors: Irene H Richard; Samuel Frank; Michael P McDermott; Hongkun Wang; Anne W Justus; Kori A LaDonna; Roger Kurlan Journal: Cogn Behav Neurol Date: 2004-12 Impact factor: 1.600
Authors: Bhagavathi S Sivamaruthi; Rajkumar Madhumita; Krishnaswamy Balamurugan; Koilmani E Rajan Journal: Front Pharmacol Date: 2015-09-04 Impact factor: 5.810
Authors: Rahul Bharatiya; Abdeslam Chagraoui; Salomé De Deurwaerdere; Antonio Argiolas; Maria Rosaria Melis; Fabrizio Sanna; Philippe De Deurwaerdere Journal: Int J Mol Sci Date: 2020-08-09 Impact factor: 5.923